SYGNIS AG / Key word(s): Conference
2015-01-14 / 10:30
SYGNIS to Present its Innovative TruePrime(TM) Technology to Next Generation Sequencing Experts at VIB’s internationally renowned Tools and Technologies Meeting
Madrid, Spain and Heidelberg, Germany, January 14th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced it will present its revolutionary novel multi displacement amplification (MDA) technology TruePrime(TM) to established experts in the field of next generation sequencing (NGS) at VIB’s Meeting “Revolutionizing Next-Generation Sequencing: Tools and Technologies” on January 15th, during the afternoon Parallel session 2 at 4:35 PM in the Kinepolis in Leuven, Belgium. This highly recognized conference is one of the key platforms for scientific players in the field of next generation sequencing worldwide.
A major challenge for next generation sequencing applications is the limited amount of DNA available, especially when working with single or a few cells gained from, for example, biopsies in cancer research. Based on the recently discovered primase TthPrimPol, SYGNIS’ TruePrime(TM) technology stands for a revolutionary change in the way the amount of DNA or RNA in a sample can be amplified. While the current gold standard in MDA needs short pieces of DNA (“oligonucleotides”) to start off whole genome amplification, TruePrime(TM) does not need any synthetic random primers.
Professor Dr. Armin Schneider, Senior Vice President Research at SYGNIS commented: “We are very proud and excited about the opportunity to introduce our next generation multiple displacement DNA amplification technology to such a selected group of experts. I am very much looking forward to discussing the outstanding advantages and the superior results that researchers can achieve when using our TruePrime(TM) MDA technology.”
More information about the VIB Meeting “Revolutionizing Next Generation Sequencing: Tools and Technologies” can be found under:
The Company is currently developing a complete range of DNA and RNA amplification kits based on its proprietary TruePrime(TM) MDA technology. The first product for whole genome amplification from single cells is expected to be launched this month.
For further information please contact:
About SYGNIS AG: www.sygnis.com
2015-01-14 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Im Neuenheimer Feld 515|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart|
|End of News||DGAP News-Service|